ABCB1 and in situ carcinoma: The anticancer drug-mediated up-regulation of FOXO3a enhances ABCB1 expression, which may directly contribute to the genesis of MDR in general and to the implicated FOXO activation-mediated chemotherapy response, including those cytostatic and cytotoxic effects amended by PTX, DCT, cisplatin (CIS), gefitinib (GEF), and 5-fluorouracil (5-FU) [10, 11].